Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of WT4869 in Patients with Myelodysplastic Syndromes
jRCT2080222621Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT4869 in myelodysplastic syndrome (MDS), sponsored by Sumitomo Pharma. Primary endpoint: Safety of long-term WT4869 administration. Started Oct 2014; status: completed.
02
Drugs
WT4869
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080222621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222621.